Trials / Unknown
UnknownNCT03675880
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
A Phase Ⅰ Clinical Study of TAB014 in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.
Detailed description
The screening period was 28 days. The classification of CNV will be determined by Fundus Fluorescein Angiography ( FFA ) at the study centers. Subjects will receive intravitreal injections of TAB014 Monoclonal Antibody Injection in one eye ( the study eye ). Subjects will only receive single intravitreal dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAB014 | TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml) |
Timeline
- Start date
- 2018-06-15
- Primary completion
- 2019-02-15
- Completion
- 2019-04-30
- First posted
- 2018-09-18
- Last updated
- 2018-09-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03675880. Inclusion in this directory is not an endorsement.